Chemotherapy-Induced Nausea and Vomiting Clinical Trial
Official title:
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after intravenous administration; the pharmacological effect of fosaprepitant is attributed to aprepitant. The birth to one year old cohort will be initiated in Parts III and IV upon completion of Part II (Steps A and B) in participants <6 months of age. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04054193 -
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
|
Phase 4 | |
| Recruiting |
NCT04430361 -
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
| Completed |
NCT02285647 -
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
|
Phase 1 | |
| Terminated |
NCT01874119 -
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01757210 -
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
|
N/A | |
| Completed |
NCT01442376 -
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
|
Phase 3 | |
| Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
| Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
| Terminated |
NCT02519842 -
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
|
Phase 3 | |
| Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
| Completed |
NCT02909478 -
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
|
Phase 3 | |
| Terminated |
NCT03237611 -
Low Dose Aprepitant for Patients Receiving Carboplatin
|
Phase 2 | |
| Completed |
NCT03649230 -
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
|
||
| Not yet recruiting |
NCT02933099 -
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 3 | |
| Completed |
NCT02557035 -
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
|
Phase 3 | |
| Completed |
NCT00787566 -
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
|
Phase 2 | |
| Completed |
NCT06121414 -
Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy
|
N/A | |
| Completed |
NCT04918069 -
Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)
|
Phase 2 | |
| Completed |
NCT05851625 -
Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients
|
N/A |